AJP - Endocrinology and Metabolism, Vol 267, Issue 1 E183-E186, Copyright © 1994 by American Physiological Society

ARTICLES

Chloroquine reduces whole body proteolysis in humans

P. De Feo, E. Volpi, P. Lucidi, G. Cruciani, F. Santeusanio, G. B. Bolli and P. Brunetti
Institute of Internal Medicine and Endocrine and Metabolic Sciences, University of Perugia, Italy.

The antimalaric drug chloroquine is a well known inhibitor of lysosomal proteolysis in vitro. The present study tests the hypothesis that therapeutic doses of the drug decrease proteolysis also in vivo in humans. Leucine kinetics were determined in 20 healthy volunteers given 12 and 1.5 h before the studies 250 and 500 mg, respectively, of chloroquine phosphate (n = 10) or similar tablets of placebo (n = 10). Chloroquine reduced the rates of leucine appearance, a measure of whole body proteolysis, from 2.45 +/- 0.08 to 2.19 +/- 0.08 mumol.kg-1.min-1 (P = 0.038) and those of nonoxidative leucine disposal, an estimate of whole body protein synthesis, from 2.16 +/- 0.08 to 1.95 +/- 0.06 mumol.kg-1.min-1 (P = 0.050). The drug resulted also in a marginally significant (P = 0.051) decrement in the plasma concentrations of glucose. The effects of chloroquine on protein turnover might be potentially useful in counteracting protein wasting complicating several catabolic diseases, whereas those on glucose metabolism can explain the sporadic occurrence of severe hypoglycemic episodes in malaria patients chronically treated with this drug.

This article has been cited by other articles:

				S. M. Weber, J.-M. Chen, and S. M. Levitz Inhibition of Mitogen-Activated Protein Kinase Signaling by Chloroquine J. Immunol., May 15, 2002; 168(10): 5303 - 5309. [Abstract] [Full Text] [PDF]

				S. M. Weber and S. M. Levitz Chloroquine Interferes with Lipopolysaccharide-Induced TNF-{alpha} Gene Expression by a Nonlysosomotropic Mechanism J. Immunol., August 1, 2000; 165(3): 1534 - 1540. [Abstract] [Full Text] [PDF]